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Summary 
Background: The immune response in patients with me la -
noma is an important focus of research due to the tumor’s
resistance and immunotherapy possibilities. IL-27 is one of
the cytokines with antitumor properties. The role of IL-27
in the pathogenesis of melanoma is still unclear. The aim
of this study was to examine the association between serum
IL-27 levels and the clinical parameters of melanoma
patients.
Methods: The IL-27 concentration was determined by
com mercial ELISA in serum samples from melanoma
patients (n=72) and healthy control subjects (n=44).
Patients were classified according to AJCC clinical stage,
TNM stage, the length of progression-free interval (PFI)
and the extent of the disease (localized or widespread). 
Results: Average IL-27 values were increased in patients
with early stages of melanoma compared to patients with
terminal stages and control values. The highest IL-27 con-
centration was found in stage IIa. Patients in stages III and
IV had significantly lower values of IL-27 compared to con-
trol. Patients with localized melanoma and shorter PFI had
insignificantly increased IL-27 levels compared to patients
with widespread disease and longer PFI. Patients with
metastatic disease and stage TNM4 had significantly lower
Kratak sadr`aj
Uvod: Pove}ana incidenca melanoma danas predstavlja je -
dan od vode}ih medicinskih problema. Imunski odgovor u
bolesnika sa melanomom predstavlja va`an fokus istra ` i -
vanja, zbog rezistentnosti ovog tumora na postoje}e vidove
terapije i mogu}nosti imunoterapije. IL-27 je jedan od cito -
kina sa antitumorskim svojstvima. Uloga IL-27 u patoge -
nezi melanoma jo{ uvek nije dovoljno rasvetljena. Cilj ove
studije bio je da se ispita povezanost vrednosti IL-27 u seru-
mu sa klini~kim parametrima bolesnika sa melanomom. 
Metode: Koncentracija IL-27 odre|ena je komercijalnim
ELISA testom u uzorcima seruma bolesnika sa melano -
mom (n=72) i zdravih kontrolnih osoba (n=44). Bolesnici
su klasifikovani prema AJCC klini~kom stadijumu, TNM
stadijumu, du`ini intervala bez progresije bolesti (PFI) i na
osnovu pro{irenosti bolesti (lokalizovana ili ra{irena). 
Rezultati: Prose~ne vrednosti IL-27 bile su pove}ane u bo les -
nika sa po~etnim stadijumima melanoma u odnosu na bo -
 lesnike sa terminalnim stadijumima i kontrolne vredno sti.
Koncentracija IL-27 je bila zna~ajno najve}a u stadijumu IIa.
Bolesnici u III i IV stadijumu imali su zna~ajno ni`e vredno -
sti IL-27 u odnosu na kontrolne. Bolesnici sa lokalizovanim
melanomom i kra}im intervalom bez progresije bolesti imali
su nezna~ajno pove}ane vrednosti u odnosu na bolesnike sa
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Introduction
Melanoma is a disease that has affected
mankind for a long time. It has been identified in Inca
mummies in Peru more than 2000 years old. The
term melanoma is derived from the Greek words
»meals« meaning black and »oma« meaning tumor.
According to the World Health Organization (WHO)
classification, there are four common types of
melanomas: superficial spreading, nodular, lentigo
maligna and acral lentiginous (1). Although mela -
noma accounts for only 4% of all skin cancers, it caus-
es the greatest number of skin cancer related deaths
worldwide. Melanoma usually affects Caucasians in
the 4th de cade of life, most commonly located on the
back of males and the legs of females. Risk factors for
the development of melanoma are pale skin, blond or
red hair, numerous freckles and tendency to burn and
tan poorly, presence of more than 50 acquired naevi,
more than five displastic naevi, chemical exposures,
immunosuppression, genetic factors, scars etc. Inter -
mittent sun exposure seems to be an important factor
(2). Episodic exposure of fair-skinned individuals to
intense sunlight is thought to be responsible for the
steadily increasing melanoma incidence worldwide
over recent decades.
Immune response to melanoma cells is well
documented, both in experimental models and in
patients (3). Spontaneous or therapy induced mela -
noma regression confirms the importance of immune
control over malignant melanocytes (4). This complex
interaction between malignant and immune cells is
regulated by numerous membrane molecules and
soluble mediators. One of them is IL-27. IL-27 is a het-
erodimeric cytokine of the IL-6/IL-12 family and con-
sists of an EBV transformed gene 3 (IL-12p40-related
protein) and p28 (IL-12p35-related protein) (5). APCs
are considered as the main source of IL-27 (6). The
expression of IL-27 has also been detected in mono-
cytes, endothelial cells, dendritic cells and trophoblast
cells (5, 7). The IL-27 receptor is composed of IL-
27Ra (also known as WSX-1 and TCCR) and gp130
(8). WSX-1 is expressed primarily in lymphoid tissues
and its expression is highest in naive T cells and NK
cells, monocytes, mast cells and neutrophils (8, 9). IL-
27 plays important roles in the early regulation of Th1
differentiation but also as an inhibitor of the immune
response (10). Moreover, IL-27 stimulates rapid clonal
expansion of naive CD4+T cells and synergizes with
IL-12 to trigger IFN-g production in naive CD4+T
cells and NK cells (5). Activation of IL-27R induces
phosphorylation of STAT 1,2,3,4 and 5 (11) and aug-
ments T-bet expression through STAT1 activation
(12). T-bet stimulates Th1 response by transactivating
the IFN-g gene. IL-27 can directly activate CD4+ and
CD8+ T cells, and induce their proliferation and dif-
ferentiation through activation of STAT3 and STAT1
(12,13) which is independent of IFN-g (14). 
It has been reported that IL-27 has the ability to
induce tumor specific antitumor and protective immu-
nity using colon carcinoma (14, 15) and TBJ neuro -
blastoma (16). Motomu Shimizu et al. showed in their
study (17) that IL-27 possesses antiangiogenic activi-
ty. Moreover, they showed the ability of IL-27 to inhib-
it tumor growth and metastasis of murine melanoma,
as well as induction of antiangiogenic chemokines.
IL-27 may be a candidate as an antitumor agent for
cancer immunotherapy thanks to its multiple mecha-
nisms, induction of CD8+T cells and NK cells, antian-
giogenic and antiproliferative activity.
In this study, we have investigated the associa-
tion of IL-27 levels with clinical parameters in
melanoma patients. 
Materials and Methods
Patients and healthy controls
Melanoma patients were recruited from the Clinic
of Dermatovenerology and Melanoma Center of the
Military Medical Academy, Medical Faculty, University of
Defense, Ministry of Defense, Belgrade, Serbia. Healthy
controls were recruited during periodical systematic
examinations of apparently healthy persons, with no
prior history of cancer. All patients and healthy controls
were consented and this study was approved by the local
Research Ethics Com mittee, Military Medical Academy
(11-03/2014). The study included 72 melanoma
patients (35 men and 37 women), and 44 healthy con-
trols (21 men and 23 women). Melanoma patients were
classified according to the 7th edition of the American
Joint Committee on Cancer (AJCC) classification for
melanoma. Characteristics of melanoma patients and
controls are shown in Table I.
average IL-27 values compared to control. Patients with
high production of IL-27 (>1000 pg/mL) were most
numerous in IIa AJCC stage, with initial tumor size TNM2
and in the group of patients with localized disease.
Conclusions: High levels of IL-27 in patients with mela -
noma are associated with the initial stages and lo calized
disease.
Keywords: antitumor response, interleukin 27, mela -
noma
metastazama i du`im intervalom bez progresije bolesti.
Bolesnici sa metastazama i TNM4 stadijumom imali su
zna~ajno ni`e prose~ne vrednosti IL-27 u odnosu na kon-
trolne. Pacijenti sa visokom produkcijom IL-27 (>1000
pg/mL) bili su najbrojniji u IIa AJCC stadijumu, sa po~etnom
veli~inom tumora TNM2 i u grupi bolesnika sa lokalizo-
vanom bole{}u. 
Zaklju~ak: Visoke vrednosti IL-27 kod bolesnika sa
melanomom povezane su sa po~etnim stadijumima i lokali-
zovanom bole{}u.
Klju~ne re~i: antitumorski odgovor, IL-27, melanoma
J Med Biochem 2016; 35 (4) 445
Samples
Venous blood was collected from melanoma
patients in vacuettes with clot activator. After isolation
(centrifugation at 3000 rpm for 10 minutes) serum
samples were frozen at –70 °C until testing (18).
Detection of IL-27
Concentration of IL-27 was measured by com-
mercial ELISA kits (Human IL-27, DuoSet,R&D, Min -
neapolis, USA).
Statistical analysis
Data analysis was performed with Graph Pad
Prism 5 software, using the nonparametric one-way
ANOVA test with Bonferroni multiple comparison
post-testing for analysis of multiple groups and Mann-
Whitney test for analysis of two groups.
Results
IL-27 values in melanoma patients groups
according to the AJCC classification
Average IL-27 concentration in melanoma patient
samples showed a clear increment tendency from the
earliest stage (Ia) up to maximal IL-27 levels in patients
with stage IIa, followed by a decrement to the lowest
average value in terminal disease stages, III and IV
(Figure 1). Control samples contained significantly less
IL-27 than those of melanoma patients with IIa

































Figure 1 IL-27 values of melanoma patients grouped according to the AJCC classification. Values are expressed as mean ± SEM.
*p<0.05, **p<0.01, c–controls.
(p=0.0064) stage but also significantly more IL-27 com-
pared to patients with IIc (p=0.0281), III (p=0.0345)
and IV (p=0.0351) AJCC stage. Finally, patients in IIa
stage had significantly elevated IL-27 compared to Ia
(p=0.0101), Ib (p=0.0095), IIb (p=0.033), IIc
(p=0.0080), III (p=0.0067) and IV stage (p=0.0360). 
IL-27 concentration in patients with localized
and widespread disease
Patients with localized disease had insignificantly
elevated average IL-27 concentrations compared to
the group with metastatic disease (Figure 2). IL-27
concentration in the control group was significantly ele -
vated compared to patients with metastatic disease
(p=0.0259).
IL-27 values association with progression free
interval (PFI)
Patients who had a PFI shorter than 24 months
had si milar average IL-27 concentrations compared to
the group with stable disease (Figure 3). Omission of
patients with high IL-27 values (>1000 pg/mL) from
both groups revealed an increased average concentra-
tion in the group with stable disease, but without statis-
tical significance.
IL-27 values in melanoma patients grouped
according to the TNM classification
According to the TNM staging, the highest aver-
age IL-27 concentration was detected in patients with
TNM2 (Figure 4). Patients with small melanomas
(TNM1) as well as patients who had TNM stage 3
had similar IL-27 concentrations, while patients with
large tumor and/or metastasis had the lowest average
IL-27 value. Again, IL-27 concentration in the control
group was significantly elevated compared to patients
with metastatic disease.
Association of clinical stage, disease spread, PFI
and TNM status with frequency of melanoma
patients with high IL-27
Analysis of IL-27 values according to the AJCC
criteria classification demonstrated that most patients
from IIa group had concentrations higher than 500
pg/mL (Table II). Identification of the so-called »high
producers«, patients whose IL-27 sera levels were
above 1000 and/or 5000 pg/mL, showed that they
are highly frequent only in IIa group, while their fre-
quency decreases below 25% in patients with more
advanced disease (stage IIc–IV). Patients with PFI
shorter or longer than 24 months did not differ in the
number of persons with IL-27 sera concentration
above 500 pg/mL. Contrary, high IL-27 producers
with shorter PFI outnumbered patients who had
longer periods of stable disease. Half of patients with
TNM1 and TNM2 stage had IL-27 values over 500
pg/mL, with gradually decreasing frequency towards
TNM4 stage. Advanced disease is inversely associat-
ed with the number of patients who had sera IL-27
above 500 pg/mL. Number of high IL-27 producers
revealed a more pronounced ratio, with almoust twice
higher frequency of those patients who had limited
disease compared to patients who had advanced
melanoma.
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Figure 2 IL-27 concentration in patients with localized and metastatic disease. Values are expressed as mean ± SEM. *p<0.05,
localized melanoma (I+II stage), metastatic melanoma (III+IV stage).
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Figure 3 IL-27 values association with progression free interval (PFI). Values are expressed as mean ± SEM. There was no sta-
tistical significance.
Figure 4 IL-27 values in melanoma patients according to TNM classification. Values are expressed as mean ± SEM. *p<0.05
Discussion
Studies from Hisada and Salcedo were the first
to report the antitumor effects of IL-27 (14, 16). The
first report of antitumor activity of IL-27 in a murine
model of colon carcinoma C26 from the Hisada
group showed that IL-27 has potent abilities to induce
tumor-specific antitumor activity and protective
immunity which is mediated through CD8+T cells,
IFN-g and T-bet but not through STAT4 (14). Results
from TBJ murine neuroblastoma tumors also demon-
strated the ability of IL-27 to induce a tumor-specific
protective immune response (16). In experimental
studies, Shimizu et al. (17) showed strong inhibition
of neovascularization by IL-27 in chicken embryos.
They also showed that IL-27 has the ability to inhibit
both tumor growth and metastasis of murine mela -
noma B16F10. Later, the Yoshimoto group (19) de -
mon strated in vitro potent antitumor effects of IL-27
on the poorly immunogenic mela noma cell line
B16F10, mediated through NK cell activity. They also
demonstrated that beyond antiproliferative activity, IL-
27 had antiangiogenic activity, inducing expression of
CCL9 and CXCL10. Authors concluded that IL-27
had antitumor effects on melanomas through WSX-
1/STAT1 signaling and proposed IL-27 as a potential
antitumor therapeutic agent. 
These data gave promising results that were
waiting to be confirmed in studies with patients.
There are still debates concerning the IL-27 function
in cancer patients. It remains unclear whether high IL-
27 concentration in patient samples is associated with
protective or insufficient antitumor response. Few
studies reported correlation of high IL-27 concentra-
tion with limited disease or good response to thera-
peutical procedures. Study of the Diakowska group
that was investigating IL-27 values in patients suffer-
ing from gastro-esophageal cancer (GEC) showed
significant increase in IL-27 concentration in GEC
patients compared to healthy controls and patients
with benign diseases of the upper parts of digestive
tract (20). Disease progression did not correlate sig-
nificantly with IL-27 concentration. Our results
showed an insignificant relationship between serum
IL-27 and stage of the disease (TNM classification)
with the highest average IL-27 level in patients with
TNM2, while the patients at stage TNM4 had the
lowest average values. Again, high IL-27 producers
were the most numerous among patients with TNM2
stage. Study of patients with gastro-esophageal can-
cer showed significant correlation between serum IL-
27 level and lymph node status (N0, N1) and positive
correlation between serum IL-27 and IFN-g. IL-27
concentration did not differ significantly between
groups of GEC patients with localized or disseminat-
ed disease. Although average IL-27 concentration
and number of high IL-27 producers were higher in
melanoma patients with localized disease, we did not
establish a significant difference between patients
with present or absent metastasis. 
Another study showed increase in IL-27 togeth-
er with VEGF concentration in patients with breast
cancer compared to control subjects (21). IL-27 value
was significantly associated with clinical stage and
increased in the group of patients whose primary
tumors were estrogen and progesterone receptor pos-
itive. The most important observation was that surgi-
cal treatment (modified radical mastectomy) was
associated with IL-27 decrement. In patients with
osteosarcoma, IL-27 concentration was significantly
associated with tumor size, with increased concentra-
tion in those with tumors larger than 7 cm (22).
Comparing the IL-27 value between groups with dif-
ferent histological types did not show any difference.
Interestingly, in this study patients without metastasis
had significantly increased IL-27 compared to those
with disseminated disease, but patients with advan -
ced clinical stage had significantly higher IL-27 com-
pared to inital (III+IV vs I+II). 








n % n % n %
AJCC
Ia (4/10) 40 (3/10) 30 (2/10) 20
Ib (14/25) 56 (8/25) 32 (6/25) 24
IIa (8/10) 80 (7/10) 70 (7/10) 70
IIb (2/7) 29 (2/7) 29 (1/7) 14
IIc (1/5) 20 (1/5) 20 (1/5) 20
III (4/11) 36 (1/11) 9 (0/11) 0
IV (1/4) 25 (0/4) 0 (0/4) 0
PFI <24 (10/22) 45 (7/22) 32 (7/22) 32
>24 (23/48) 48 (16/48) 33 (11/48) 23
TNM 1 (18/35) 51 (11/35) 31 (8/35) 23
2 (11/22) 50 (10/22) 45 (9/22) 41
3 (4/10) 40 (3/10) 30 (2/10) 20
4 (1/5) 20 (0/5) 0 (0/5) 0
Disease
Spread
I+II (29/57) 51 (21/57) 37 (17/57) 30
III+IV (5/12) 42 (3/12) 25 (2/12) 17
Control (29/44) 66 (13/44) 30 (6/44) 14
Table II Frequency of melanoma patients with IL-27 value
above 500, 1000 and 5000 pg/mL
Two studies in lung cancer patients further high-
lighted the IL-27 importance. Naumnik et al. showed
that IL-27 increment in broncho-alveolar fluid sam-
ples is associated with partial remission after
chemotherapy (23). Duan et al. (24) found that
NSCLC patients had significantly decreased average
serum IL-27 concentrations compared to healthy
controls (241 vs 320 pg/mL) and that IL-27 negative-
ly correlated with blood Th17 cells percentage. Study
on prostate cancer demonstrated the antitumor
potential of IL-27 through inhibition of cell prolifera-
tion and by inducing apoptosis (25). Authors of this
study showed that IL-27 downregulated pro-angio-
genic genes such as vascular endothelial growth fac-
tor receptor (VEGFR)1/FLT1, fibroblast growth factor
receptor 3 (FGFR3) and prostaglandin G/H synthase
1. IL-27 negatively regulates octeoclastogenesis and
could even modulate interactions between prostate
tumor and bone cells, which is important in treating
meta static pro state tumors (26). 
Zhou et al. (27) demonstrated that patients with
noninvasive bladder cancer had significantly de crea sed
IL-27 compared to controls (21 vs 38 pg/mL). They
found no significant differences in IL-27 concentration
between invasive and noninvasive types of bladder can-
cer, nor between patients with high grade and low
grade disease. Study by the Gonin group (28) demon-
strated completely different data from the study of
Zhou et al. (27). Analysis of IL-27 expression in pri-
mary cutaneous melanoma samples showed absence
of IL-27 in benign pigment and noninvasive mela -
noma lesions, but intensive expression of IL-27 in pri-
mary invasive melanomas. In the IL-27 positive tu -
mors, this cyto kine was localized in macrophages,
tumor infiltrating cells, melanophages, but also in
tumor cells. Further more, patients with IL-27 positive
tumors who suffered from disseminated disaese also
had their metastasis positive for IL-27. Authors con-
cluded that IL-27 expression in melanoma tissue was
associated with disease progression, but not regres-
sion of tumor. 
To our knowledge, this study is the first that
investigated the IL-27 concentration in sera samples
of mela noma patients. According to clinical staging,
patients who were IIa stage had the highest average
IL-27 level. Average IL-27 concentration had a clear
decreasing trend toward patients with advanced dis-
ease. The frequency of high IL-27 producers also
decreased together with progression of disease. The
average value of IL-27 between groups PFI>24 and
PFI<24 did not differ significantly, but the frequency
of high IL-27 producers (IL-27>5000 pg/mL) was
higher in the group with shorter PFI.
Taken together, the results of our study indicate a
protective role of IL-27 in patients with melanoma.
Understanding the role of IL-27 in the pathogenesis of
melanoma could be useful for optimal control of the
immune response against tumors. IL-27 could be valu-
able in the estimation of ongoing antitumor response.
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